Muscle atrophy

New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA

Retrieved on: 
Wednesday, January 10, 2024
Fruit, Patient, Rosaceae, Research, Facial muscles, Associate, Delayed onset muscle soreness, BAG3, Carica, Multimedia, Hong Kong Baptist University, Muscular dystrophy, Myopathy, Disability studies, Prescription, HKBU, Traditional Chinese medicine, Disease, Safety, FDA, Pain, Caricaceae, Investigational New Drug, Agonal respiration, Cardiomyopathy, Paralysis, Muscle atrophy, Pharmaceutical industry

The drug has obtained the orphan drug designation from the US Food and Drug Administration (FDA), and is the first botanical drug in Hong Kong to receive this qualification.

Key Points: 
  • The drug has obtained the orphan drug designation from the US Food and Drug Administration (FDA), and is the first botanical drug in Hong Kong to receive this qualification.
  • The research team plans to submit an Investigational New Drug application to FDA in two years to conduct clinical trials.
  • Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) and Director of the Centre for Chinese Herbal Medicine Drug Development at HKBU, said: "CDD-2107 is the fruit of the integration of Chinese medicine theory and modern technology.
  • Receiving the orphan drug designation by FDA for CDD-2107 is an encouraging milestone and recognition of our team's dedication to scientific innovation."

Immunis Chairman Dr. Hans Keirstead to Speak at the Longevity Investors Lunch in Davos

Retrieved on: 
Monday, January 8, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Conference, Metabolism, Regenerative medicine, Longevity, Ageing, Genomics, Muscle atrophy, Patient, Safety, Therapy, Notifiable disease, Lunch

Immunis, Inc., a private biotech and a pioneering force in cellular secretome therapeutics, is thrilled to announce that its Chairman, Dr. Hans Keirstead , is an invited speaker at the exclusive Longevity Investors Lunch in Davos, Switzerland (hosted by Longevity Investors Conference).

Key Points: 
  • Immunis, Inc., a private biotech and a pioneering force in cellular secretome therapeutics, is thrilled to announce that its Chairman, Dr. Hans Keirstead , is an invited speaker at the exclusive Longevity Investors Lunch in Davos, Switzerland (hosted by Longevity Investors Conference).
  • The conference will emphasize the importance of innovative therapeutic approaches in aging and longevity, showcasing cutting-edge developments in cellular therapies, genomics, and age-related disease management.
  • Dr. Hans Keirstead, a distinguished leader in the biotech industry known for his entrepreneurial success and pioneering contributions in regenerative medicine, will present Immunis’ latest data on its investigational secretome, IMMUNA.
  • This Longevity Investors’ event is a catalyst for the fusion of academic inquiry and industrial innovation, shaping the trajectory of future medical interventions in longevity and aging.

NASA to Provide Coverage as Dragon Departs Station with Science

Retrieved on: 
Wednesday, December 20, 2023
Atmosphere, Space Station Processing Facility, International Space Station, Biology, EST, SpaceX Dragon, Multimedia, Biotechnology, Drug development, Blog, SpaceX launch vehicles, JAXA, DNA, Plant, NASA, Kennedy Space Center, Osteoporosis, Social media, SpaceX, Muscle atrophy, Transport, Spacecraft, Gene, Harmony, Television, Artemis, Orbit, NASA TV, Communications satellite

The agency will provide live coverage of Dragon's undocking and departure starting at 8:45 p.m. EST on the NASA+ streaming service via the web or the NASA app .

Key Points: 
  • The agency will provide live coverage of Dragon's undocking and departure starting at 8:45 p.m. EST on the NASA+ streaming service via the web or the NASA app .
  • Coverage also will air live on NASA Television, YouTube , and on the agency's website .
  • NASA will not broadcast the splashdown, but updates will be posted on the agency's space station blog.
  • Dragon arrived at the station Nov. 11 as SpaceX's 29th commercial resupply services mission for NASA, delivering about 6,500 pounds of research investigations, crew supplies, and station hardware.

Muscle Wasting Disorders Market Predicted to Reach USD 45.4 Billion by 2031, Garnering 15.1% CAGR: TMR Report

Retrieved on: 
Monday, October 30, 2023
Developed country, Research, ALS, Muscle atrophy, Cancer, Patient, Muscular dystrophy, Atrophy, Pharmaceutical industry, Dietary supplement

WILMINGTON, Del., Oct. 30, 2023 /PRNewswire/ -- The muscle wasting disorders market generated revenues worth US$ 12.7 billion in 2022. The market is predicted to reach US$ 45.4 billion in 2031. Between 2023 and 2031, the market is expected to register a growth rate of 15.1%.

Key Points: 
  • Physiological atrophy is expected to dominate the market for muscle wasting disorders.
  • Regulatory agencies are increasingly recognizing muscle wasting disorders, and promising therapies are receiving incentives and fast-track designations.
  • Increased government funding for research, increased cancer awareness in developing countries, and patient support programs are expected to boost the muscle wasting disorders market in the future.
  • Key market players in the muscle wasting disorders landscape include:

Muscle Wasting Disorders Market Predicted to Reach USD 45.4 Billion by 2031, Garnering 15.1% CAGR: TMR Report

Retrieved on: 
Monday, October 30, 2023
Developed country, Research, ALS, Muscle atrophy, Cancer, Patient, Muscular dystrophy, Atrophy, Pharmaceutical industry, Dietary supplement

WILMINGTON, Del., Oct. 30, 2023 /PRNewswire/ -- The muscle wasting disorders market generated revenues worth US$ 12.7 billion in 2022. The market is predicted to reach US$ 45.4 billion in 2031. Between 2023 and 2031, the market is expected to register a growth rate of 15.1%.

Key Points: 
  • Physiological atrophy is expected to dominate the market for muscle wasting disorders.
  • Regulatory agencies are increasingly recognizing muscle wasting disorders, and promising therapies are receiving incentives and fast-track designations.
  • Increased government funding for research, increased cancer awareness in developing countries, and patient support programs are expected to boost the muscle wasting disorders market in the future.
  • Key market players in the muscle wasting disorders landscape include:

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization

Retrieved on: 
Thursday, October 26, 2023
Health, Fitness & Nutrition, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Science, Lilly, Eli Lilly and Company, Ageing, Concept, Biomarker, Therapy, Heart, Obesity, Weight loss, Apelin, Doctor of Philosophy, Agonal respiration, Maintenance, Exercise, Metabolism, Drug development, Incretin, Muscle atrophy, Biology, Amgen, Bed rest, Chemistry, Central nervous system, Pharmaceutical industry, Dietary supplement, Chorus

As part of the collaboration, Lilly will also provide BioAge with tirzepatide.

Key Points: 
  • As part of the collaboration, Lilly will also provide BioAge with tirzepatide.
  • “We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s expertise in obesity drug development,” said Kristen Fortney, PhD, CEO and co-founder of BioAge.
  • “Our Phase 2 trial is designed to assess whether azelaprag can substantially increase the weight loss achieved with drugs of the incretin class.
  • Apelin signaling has demonstrated multiple benefits in energy metabolism in mouse models, including increased insulin sensitivity and reduction in fat mass.

Immunis Chief Business Officer Mark Cabato to Deliver Keynote at the Drug Discovery Strategic Summit

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Muscle atrophy, Therapy, Metabolism, Conference, Quality of life, Pharmaceutical industry

Immunis, Inc., a leading biotechnology company forging innovative cellular secretome therapies for age and disease-related immune decline, is delighted to announce that its Chief Business Officer, Mark Cabato, will be a keynote speaker at this year's Drug Discovery Strategic Summit .

Key Points: 
  • Immunis, Inc., a leading biotechnology company forging innovative cellular secretome therapies for age and disease-related immune decline, is delighted to announce that its Chief Business Officer, Mark Cabato, will be a keynote speaker at this year's Drug Discovery Strategic Summit .
  • Mark is set to delve deeper into Immunis' cutting-edge cellular secretome technology, which has shown pre-clinical efficacy in improving muscle regeneration and function as well as benefiting metabolism.
  • The investigational secretome product, IMMUNA, is currently being tested in a Phase 1/2a clinical trial in elderly adults with muscle atrophy.
  • The Drug Discovery Strategic Summit has historically been a melting pot for revolutionary ideas in the medical world.

Immunis Chairman Dr. Hans Keirstead to Present at Innovative Therapies Days in France

Retrieved on: 
Monday, October 9, 2023
Surgery, Other Health, Other Science, Pharmaceutical, Research, Oncology, Medical Devices, Infectious Diseases, Hospitals, Technology, Genetics, Fitness & Nutrition, Clinical Trials, Stem Cells, Science, Biotechnology, Practice Management, Seniors, Physical Therapy, Nanotechnology, Alternative Medicine, Managed Care, Medical Supplies, FDA, Health, Diabetes, Consumer, Muscle atrophy, Metabolism, B cell, Innovation, Pharmaceutical industry, Medical device, Faxonius immunis

Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, is pleased to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Innovative Therapies Days conference in Besançon, France.

Key Points: 
  • Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, is pleased to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Innovative Therapies Days conference in Besançon, France.
  • Innovative Therapies Days is a premier event in medical innovation, showcasing presentations from esteemed clinicians, scientists, and industry partners.
  • At Immunis, Dr. Keirstead leads a team that stands at the forefront of biotech innovation.
  • By bridging the gap between academic research and industrial applications, the Innovative Therapies Days aims to chart the course for the next era of medical treatment.

Immunis Chairman Dr. Hans Keirstead to Present at the Festival of Biologics in Basel

Retrieved on: 
Tuesday, September 26, 2023
Research, Infectious Diseases, Seniors, Neurology, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Festival, Drug discovery, Regenerative medicine, Osteoarthritis, Global health, Patient, Muscle atrophy, Pharmaceutical industry

Immunis, Inc., a private biotech developing innovative cellular secretome therapies for age and disease-related immune decline, is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland.

Key Points: 
  • Immunis, Inc., a private biotech developing innovative cellular secretome therapies for age and disease-related immune decline, is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland.
  • The Festival of Biologics is a pivotal meeting for the life science community, encompassing the entire spectrum of biologics, from drug discovery and development to manufacturing, clinical trials, and commercialization.
  • Dr. Keirstead's presence supports Immunis' position at the forefront of biotechnological research and dedication to enhancing global health through innovation.
  • “We're incredibly proud to have Dr. Keirstead represent Immunis at such a significant event,” remarked Senior Scientific Communications Manager, Dr. Karissa Munoz.

Immunis Chairman Dr. Hans Keirstead to Present at the Festival of Biologics in Basel

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Research, Medical Devices, Infectious Diseases, Hospitals, Fitness & Nutrition, Women, Science, Seniors, Technology, Clinical Trials, Medical Supplies, Biotechnology, Nanotechnology, FDA, Alternative Medicine, Surgery, Men, Diabetes, Health, Consumer, Stem Cells, Practice Management, Physical Therapy, Managed Care, Other Health, Pharmaceutical, Other Science, Festival, Drug discovery, Regenerative medicine, Osteoarthritis, Global health, Patient, Muscle atrophy, Pharmaceutical industry

Immunis, Inc., a private biotech developing innovative cellular secretome therapies for age and disease-related immune decline, is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland.

Key Points: 
  • Immunis, Inc., a private biotech developing innovative cellular secretome therapies for age and disease-related immune decline, is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland.
  • The Festival of Biologics is a pivotal meeting for the life science community, encompassing the entire spectrum of biologics, from drug discovery and development to manufacturing, clinical trials, and commercialization.
  • Dr. Keirstead's presence supports Immunis' position at the forefront of biotechnological research and dedication to enhancing global health through innovation.
  • “We're incredibly proud to have Dr. Keirstead represent Immunis at such a significant event,” remarked Senior Scientific Communications Manager, Dr. Karissa Munoz.